ADHD
The quest to understand and treat a pervasive and mystifying mental health condition.
ADHD
The quest to understand and treat a pervasive and mystifying mental health condition.
Produced with support from:
This Nature Outlook is editorially independent, produced with financial support from Otsuka America Pharmaceutical. About this content.The symptoms of attention deficit hyperactivity disorder (ADHD) have been known for more than 100 years, although the condition was not formally recognized until the 1960s and did not receive its current name until 1980.
Globally, ADHD affects up to 8% of children and adolescents, and often persists into adulthood. Rates have been rising quickly over the past few decades, for reasons that are not entirely clear — a mystery that underscores how much we still have to learn about the condition.
Features and comment
Original journalism from Nature.
FEATURE
Is paracetamol in pregnancy a risk factor for ADHD?
A common pain reliever taken in pregnancy might raise the risk of attention deficit hyperactivity disorder, according to research in the past decade. But proof of cause and effect remains elusive. By Carolyn Brown
21 January 2026
FEATURE
ADHD treatments move beyond stimulants
Researchers are developing drugs to broaden the options on available therapies. By Nicola Jones
21 January 2026
Q&A
Why ADHD goes undiagnosed in girls
Clinical psychologist Julia Schechter explains how its presentation and co-occurring psychiatric conditions make detection difficult in girls.
21 January 2026
RESEARCH ROUND-UP
Six highlights from ADHD research
Key studies and trials examine genetic mutations, the impact on life expectancy, cognitive impairments and other aspects of this condition. By Simon Makin
21 January 2026
VIDEO
ADHD: why do women like me get diagnosed late?
Emily Bates was diagnosed with ADHD at the age of 34. She explores how the condition presents in women and why so many are diagnosed later in life.
21 January 2026
FEATURE
Untangling the connection between dopamine and ADHD
Dopamine signals have long been a target for ADHD treatments. Now, researchers are learning how the neurotransmitter influences the condition. By Jyoti Madhusoodanan
21 January 2026
FEATURE
Why teens with ADHD are so vulnerable to the perils of social media
For many young people with the condition, screen interactions are especially hard to resist — and intensify the mental-health challenges they face. By Elie Dolgin
21 January 2026
More from Nature Outlook
Pancreatic cancer
Glimmers of hope for a deadly and challenging disease.
Cities
The future of humanity depends on the health and happiness of urban dwellers.
Alzheimer's disease
Treatments and better diagnostics change perspectives on cognitive erosion.
Skin
Protecting and repairing the most visible part of the body.
Research and reviews
Curated from the Nature Portfolio journals.
Nature is pleased to acknowledge financial support from Otsuka America in producing this Outlook. Nature retains sole responsibility for all editorial content. About this content.
The supporting organization retains sole responsibility for the following message:
Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. are the US-based indirect subsidiaries of the global healthcare company Otsuka Pharmaceutical Co. Ltd with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka’s US companies share a deep commitment to the development and commercialization of innovative products in the spaces of neuroscience, nephrology, and immunology.
At Otsuka, we hold a deep respect for the value of every mind. We will not rest until mental illnesses and brain diseases are approached with the same priority and urgency as our physical health and recognized as chronic diseases that warrant early, equitable, and accessible intervention for patients and caregivers everywhere.
Editorial Brian Owens, Herb Brody, Richard Hodson, Nick Haines, Jenny McCarthy
Art & Design Mohamed Ashour, Marian Karam, Madeline Hutchinson
Production Nick Bruni, Khuram Rashid, Natalie Smith
Sponsorship Stephen Brown
Marketing Kimberly Petit
Project Manager Nada Nabil












